Sandra Plachta-Danielzik
Overview
Explore the profile of Sandra Plachta-Danielzik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schulz F, Foldenauer A, Weidmann L, Thomann A, Tal A, Plachta-Danielzik S, et al.
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768729
Inflammatory bowel disease (IBD) remains an incurable illness. Patients with IBD show gender-specific differences in various aspects of the disease. There is still uncertainty about the causality of the differences....
2.
Fedde S, Stolte A, Plachta-Danielzik S, Muller M, Bosy-Westphal A
Pediatr Obes
. 2024 Dec;
:e13192.
PMID: 39622513
Objective: The aim was to assess ultra-processed food (UPF) consumption, its impact on overweight and its association with weight trends from childhood and adolescence to young adulthood. Methods: Long-term UPF...
3.
Mannion E, Bihrmann K, Plachta-Danielzik S, Muller M, Bosy-Westphal A, Ritz C
Nutrients
. 2024 Sep;
16(18).
PMID: 39339820
Background: This study investigated potential subgroups of children within the Kiel Obesity Prevention Study (KOPS) for differing treatment effects for the outcome measures of overweight or obesity at 4 years....
4.
Bokemeyer B, Plachta-Danielzik S, Steiner I, Pohlschneider D, Urzica E, Hartmann P, et al.
Aliment Pharmacol Ther
. 2024 Mar;
59(9):1082-1095.
PMID: 38429885
Background: IBD was a randomised controlled trial assessing the efficacy of care provided by IBD nurse specialists in Germany in improving health-related quality of life (QoL) in IBD patients on...
5.
Bokemeyer B, Plachta-Danielzik S
Aliment Pharmacol Ther
. 2023 Nov;
59(1):142-143.
PMID: 37924219
No abstract available.
6.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, et al.
Inflamm Bowel Dis
. 2023 Jul;
30(5):746-756.
PMID: 37523666
Background: The aim of this observational, real-world evidence, modified intention-to-treat (mITT) study based on prospectively collected data from the VEDOIBD registry was to compare the effectiveness of vedolizumab (VEDO) vs...
7.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Krause T, et al.
Aliment Pharmacol Ther
. 2023 Jun;
58(4):429-442.
PMID: 37322825
Background: This observational real-world evidence (RWE) study is based on prospectively collected data from the VEDO registry study. Aim: To compare the effectiveness of vedolizumab and anti-TNF agents in biologic-naïve...
8.
Plachta-Danielzik S, Grasskemper L, Schmidt K, Schreiber S, Bokemeyer B
JMIR Res Protoc
. 2023 May;
12:e42574.
PMID: 37155235
Background: Filgotinib was approved in Germany for treating patients with moderate to severe active ulcerative colitis in November 2021. It represents a preferential Janus kinase 1 inhibitor. The FilgoColitis study...
9.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Helwig U, Teich N, Schmidt C, et al.
Aliment Pharmacol Ther
. 2023 Apr;
58(1):35-47.
PMID: 37051808
Objective: Under the assumption of irreversibility, the Montreal classification provides a unidirectional assessment of the complications and behaviour of Crohn's disease (CD) that does not allow for downstaging. We examined...
10.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Mohl W, Teich N, Hoffstadt M, et al.
Inflamm Bowel Dis
. 2023 Jan;
29(11):1741-1750.
PMID: 36633301
Background: In addition to randomized controlled trials (RCTs), real-world studies on the effectiveness of ustekinumab (UST) in Crohn's disease (CD) are required inasmuch as RCTs are usually confined to selected...